Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401

Editas Medicine is preparing to initiate a first-in-human study of EDIT-401, an in vivo CRISPR-edited therapy intended to reduce LDL cholesterol in patients with heterozygous familial hypercholesterolemia. The clinical progression is a positive milestone for Editas's gene-editing pipeline, though efficacy and safety data have not yet been reported.